Case Report: Diabetic ketoacidosis following EGFR-TKIs therapy via aggravated insulin resistance.
This case report, published in Frontiers in Oncology, describes a diabetic patient who developed diabetic ketoacidosis (DKA), a serious complication, after starting treatment with EGFR-TKIs, a type of targeted cancer therapy. The patient had type 2 diabetes and was being treated for lung cancer. The study suggests that EGFR-TKIs may worsen insulin resistance, leading to high blood sugar and DKA. The report highlights the need for careful monitoring of blood sugar in diabetic patients receiving this cancer treatment. The findings are important because EGFR-TKIs are commonly used in China, and many patients with cancer also have diabetes. However, this is a single case, so more research is needed to confirm the risk and understand how common it is. Patients on EGFR-TKIs should have regular blood sugar checks and be aware of symptoms of DKA, such as excessive thirst, frequent urination, and fatigue.
Key takeaways
- EGFR-TKIs, a targeted cancer therapy, may increase blood sugar and cause diabetic ketoacidosis in diabetic patients, as shown in this case report.
- A diabetic lung cancer patient developed DKA after starting EGFR-TKI treatment, suggesting the drug worsened insulin resistance.
- This case underscores the importance of monitoring blood sugar and educating patients about DKA symptoms during EGFR-TKI therapy.
- If you are diabetic and starting EGFR-TKIs, ask your doctor how often to check your blood sugar and what to do if it rises.
- More research is needed to understand how common this complication is and to develop guidelines for managing diabetes during EGFR-TKI treatment.
- For DFU patients in China, this case highlights the need to manage diabetes aggressively, especially when taking other medications that affect blood sugar.
Read the full paper / source →
This content summarizes published medical research for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making treatment decisions.
Free consultation
Could this treatment help you?
Our DFU specialists review every inquiry personally. Tell us about your situation — response within 48 hours, no commitment required.
This website provides medical-information science popularization only. It does NOT provide online diagnosis, prescriptions, or medical advice. Consult a licensed physician for any medical decision.
Editor's note
This case report serves as a critical reminder for diabetic patients in China, especially those with diabetic foot ulcers, to closely monitor their blood sugar when starting new medications. EGFR-TKIs are widely used in China for lung cancer, but concurrent diabetes management is essential. While this is a rare report, it highlights the need for multidisciplinary care involving oncologists and endocrinologists. Patients should discuss blood sugar monitoring plans with their doctors, particularly in specialised DFU centres where holistic care is provided.